Investigational Drug Details
| Drug ID: | D251 |
| Drug Name: | OKT3 |
| Synonyms: | Anti-CD3; Muromonab-CD3 |
| Type: | Biological drug |
| DrugBank ID: | DB00075 |
| DrugBank Description: | Murine monoclonal antibody specific to CD3 T-cell lymphocyte antigens. More specifically it is a purified murine (mouse) monoclonal antibody, directed against the CD3 (T3) receptor on the surface of human T-cells (T-lymphocytes) cultured using the murine ascites method. Muromonab is 93% monomeric immune globulin G type 2a (IgG2a). |
| PubChem ID: | -- |
| CasNo: | 140608-64-6 |
| Repositioning for NAFLD: | Yes |
| SMILES: | -- |
| InChiKey: | -- |
| Molecular Weight: | -- |
| DrugBank Targets: | T-cell surface glycoprotein CD3 delta chain; T-cell surface glycoprotein CD3 epsilon chain binder; T-cell surface glycoprotein CD3 gamma chain; T-cell surface glycoprotein CD3 zeta chain; Low affinity immunoglobulin gamma Fc region receptor III-B |
| DrugBank MoA: | Muromonab binds to the T-cell surface glycoprotein CD3 epsilon chain. It appears to kill CD-3 positive cells by inducing Fc mediated apoptosis, antibody mediated cytotoxicity and complement-dependent cytotoxicity. |
| DrugBank Pharmacology: | Used in organ transplant prophylaxis, Muromonab or OKT-3 binds specifically to the CD-3 complex, which is involved in antigen recognition and cell stimulation, on the surface of T lymphocytes. Immediately after administration CD-3-positive T lymphocytes are abruptly removed from circulation. It has been effective in reversing corticosteroid-resistant acute rejection in renal, liver, and cardiac transplant recipients. |
| DrugBank Indication: | For treatment of organ transplant recipients, prevention of organ rejection |
| Targets: | CD3E antagonist |
| Therapeutic Category: | Immunosuppressant |
| Clinical Trial Progress: | Phase 2 completed (NCT01205087) |
| Latest Progress: | Under clinical trials |
| Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted | |
|---|---|---|---|---|---|---|---|
| L0333 | NCT01205087 | Phase 2 | Completed | No Results Available | September 2010 | June 23, 2011 | Details |
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Article ID | PMID | Source | Title | |
|---|---|---|---|---|
| A20574 | 25876706 | J Clin Immunol | Oral Administration of OKT3 MAb to Patients with NASH, Promotes Regulatory T-cell Induction, and Alleviates Insulin Resistance: Results of a Phase IIa Blinded Placebo-Controlled Trial. | Details |
| A48204 | 19881519 | Nat Rev Gastroenterol Hepatol | Liver transplantation after radioembolization in a patient with unresectable HCC. | Details |